menu
    • menu
    [{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Lapam Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"LTZ-301","moa":"CD79b\/B-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Lapam Capital","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Lapam Capital"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"LTZ-301","moa":"CD79b\/B-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LTZ-301","moa":"CD79b\/B-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LTZ-301","moa":"CD79b\/B-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by LTZ Therapeutics

    Menu

    LTZ Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LTZ Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            LTZ Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTZ-301

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LTZ Therapeutics Announces FDA Clearance of IND Application for LTZ-301

                            Details : LTZ-301 is a CD79B inhibitor, cell therapy candidate, which is currently being evaluated for the treatment of relapsed or refractory non-Hodgkin lymphoma.

                            Product Name : LTZ-301

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 24, 2025

                            Lead Product(s) : LTZ-301

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LTZ Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            LTZ Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTZ-301

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LTZ Therapeutics Gets FDA IND Clearance for LTZ-301 Myeloid Engager Trial

                            Details : LTZ-301 is a CD79B/B-cell inhibitor, cell therapy candidate, which is currently being evaluated for the treatment of relapsed or refractory non-Hodgkin lymphoma.

                            Product Name : LTZ-301

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 24, 2025

                            Lead Product(s) : LTZ-301

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            LTZ Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            LTZ Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTZ-301

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Lapam Capital

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            LTZ Therapeutics Announces $20M Series A for Myeloid Engager-Based Immunotherapy Pipeline

                            Details : The proceeds from the financing will be used to accelerate the development of LTZ’s pipeline, support the company’s IND process, and initiate the Ph 1 clinical study for treating B-cell Lymphoma.

                            Product Name : LTZ-301

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 30, 2024

                            Lead Product(s) : LTZ-301

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Lapam Capital

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            LTZ Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            LTZ Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTZ-301

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Qiming Venture Partners

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat ...

                            Details : The net proceeds from the financing will be used to continue establishing the company’s platform and pipeline, including LTZ-301 being developed for the treatment of Non-Hodgkin's lymphoma and Chronic lymphocytic leukemia.

                            Product Name : LTZ-301

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 31, 2023

                            Lead Product(s) : LTZ-301

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Qiming Venture Partners

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth